Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
Glatiramer acetate (GA) is an approved drug for therapy of relapsing remitting MS that acts as a T cell antigen. Here, we report the cloning of HLA restricted, GA-specific human CD8(+) T cells. In addition, we analyzed the cytokine profile of GA-reactive CD8(+) T cell lines. Unexpectedly, IL-4 was increased in untreated MS patients as compared to healthy individuals (p<0.001). In GA-treated patients, however, IL-4 (p<0.001), IL-10 (p<0.001) and TNF-alpha (p<0.001) were decreased. Thus, while GA is known to induce a TH2 bias in CD4(+) T cells, we detected a distinct pattern in GA-reactive CD8(+) T cells.
Dressel
Alexander
A
Department of Neurology, Ernst Moritz Arndt University Greifswald, Sauerbruchstr., 17489 Greifswald, Germany. adressel@neurologie.uni-greifswald.de
Vogelgesang
Antje
A
Brinkmeier
Heinrich
H
Mäder
Michael
M
Weber
Frank
F
D000328:Adult; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D002999:Clone Cells; D000939:Epitopes / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology*; D010455:Peptides / Q000008:administration & dosage*
D000939:Epitopes; D007166:Immunosuppressive Agents; D010455:Peptides; D015847:Interleukin-4; D000068717:Glatiramer Acetate; D007371:Interferon-gamma